Biosimilars, a rapidly evolving field in biopharmaceutics, represent a groundbreaking category of therapeutic agents. These biological products, akin to existing biologics, are designed to demonstrate comparable efficacy, safety, and quality. Unlike generic drugs, biosimilars are complex and intricately manufactured, often involving living organisms.
The development of biosimilars is a result of advancements in biotechnology, allowing for the replication of intricate structures found in biopharmaceuticals. These products not only expand patient access to life-changing treatments but also contribute to healthcare affordability.
Biopharmaceutics focuses on understanding the complex interplay between biological systems and pharmaceutical formulations. Biosimilars, being part of this realm, undergo rigorous testing to ensure they meet stringent regulatory standards. As the industry continues to grow, the promise of biosimilars lies in their potential to enhance treatment options, promote competition, and foster innovation in the biopharmaceutical landscape.
Title : The impact of metal-decorated polymeric nanodots on proton relaxivity
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil